Experiment Overview
| Repository ID: | FR-FCM-Z5PZ | Experiment name: | KEYNOTE001_UCLA_CYTOF | MIFlowCyt score: | 29.99% |
| Primary researcher: | Philippe ROCHIGNEUX | PI/manager: | Philippe ROCHIGNEUX | Uploaded by: | Philippe ROCHIGNEUX |
| Experiment dates: | 2018-07-01 - 2022-09-04 | Dataset uploaded: | Sep 2022 | Last updated: | Sep 2022 |
| Keywords: | [immunotherapy] [pembrolizumab] [immune monitoring] [lung cancer] [immune biomarker] [mass cytometry.] | Manuscripts: | |||
| Organizations: |
UCLA, Cytometry Core, Los Angeles, (USA)
|
||||
| Purpose: | to discover blood baseline immune predictors of pembrolizumab efficacy in advanced NSCLC | ||||
| Conclusion: | see Rochigneux et al., Cancer Research 2022 (in press) | ||||
| Comments: | None | ||||
| Funding: | Fondation de France UNICANCER, Institut Paoli-Calmettes, grant of FRM (Equipe FRM 2018 DEQ20180339209), SIGN’IT grant from Fondation ARC, grant NIH-NCI K08 CA245249-01A1, LUNGevity 2019 Career Development Award,NIH grant (R01 CA208403). | ||||
| Quality control: | in each CYTOF acquisition (barcoded samples), the same healthy donnor was included to minimize batch effect. | ||||
